Currently, there are 61.63M common shares owned by the public and among those 44.02M shares have been available to trade.
The company’s stock has a 5-day price change of 1.65% and 0.82% over the past three months. PYXS shares are trading -21.15% year to date (YTD), with the 12-month market performance down to -69.25% lower. It has a 12-month low price of $0.83 and touched a high of $5.39 over the same period. PYXS has an average intraday trading volume of 544.41K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 7.99%, 14.86%, and -44.21% respectively.
Institutional ownership of Pyxis Oncology Inc (NASDAQ: PYXS) shares accounts for 37.56% of the company’s 61.63M shares outstanding.
It has a market capitalization of $76.20M and a beta (3y monthly) value of 1.18. The earnings-per-share (ttm) stands at -$1.58. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.19% over the week and 5.99% over the month.
Analysts forecast that Pyxis Oncology Inc (PYXS) will achieve an EPS of -0.35 for the current quarter, -0.35 for the next quarter and -1.22 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.36 while analysts give the company a high EPS estimate of -0.36. Comparatively, EPS for the current quarter was -0.29 a year ago. Earnings per share for the fiscal year are expected to decrease by -4.29%, and 13.20% over the next financial year. EPS should grow at an annualized rate of 2.24% over the next five years, compared to -74.92% over the past 5-year period.
Stephens coverage for the Pyxis Oncology Inc (PYXS) stock in a research note released on November 08, 2024 offered a Overweight rating with a price target of $13. Stifel was of a view on August 08, 2024 that the stock is Buy, while Jefferies gave the stock Buy rating on May 07, 2024, issuing a price target of $10. BTIG Research on their part issued Buy rating on February 09, 2024.
